SIM
ALXN

SSI Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

SSI Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,723
Closed -$263K – 417
2014
Q1 		$263K Sell
1,723
-2,828
-62% -$450K 0.03% 343
2013
Q4 		$605K Sell
4,551
-1,326
-23% -$159K 0.05% 314
2013
Q3 		$683K Sell
5,877
-1,780
-23% -$195K 0.06% 262
2013
Q2 		$706K Buy
+7,657
New +$738K 0.07% 260

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SSI Investment Management's ALXN Position: Q2 2014 in Review

SSI Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 1,723 shares — an estimated $263K sold.

SSI Investment Management first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $706K in Q2 2013. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • SSI Investment Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SSI Investment Management sold 1,723 Alexion Pharmaceuticals shares in Q2 2014, an estimated $263K.
  • SSI Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SSI Investment Management's Alexion Pharmaceuticals position peaked at $706K in Q2 2013.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on SSI Investment Management's 13F filing for Q2 2014, filed 8 Aug 2014.